Guggenheim raises Genmab stock price target on pipeline potential
Guggenheim raised its price target for Genmab (NASDAQ:GMAB) to $54 from $45, citing confidence in its R&D pipeline, including Rina-S. The stock is near its 52-week high and has gained 26% in six months. Genmab reported Q2 2026 earnings of $4.91 per share, exceeding estimates, and raised 2026 revenue guidance to DKK 4.3-4.5 billion. H.C. Wainwright maintains a Buy rating with a $40 target.
How this was made
The 30-second read
Why it matters
The upgrade could trigger short‑term buying pressure and attract new institutional interest.
Market read
Genmab's stock may rally on the upgraded target and strong Q2 results, with broader biotech sentiment potentially benefiting peers.
What to watch
Potential regulatory delays for Rina‑S and competition in the ovarian‑cancer market.
Background
Analyst price‑target upgrades often move small‑cap biotech stocks, especially when paired with recent earnings beats and pipeline progress.
Ticker impact
Guggenheim raised its price target on Genmab to $54 and highlighted strong late‑stage pipeline data and Q2 earnings beat.
upward pressure as investors price in the higher target and pipeline upside.
The new $54 target implies ~55% upside from current price and reflects improved success assumptions for Rina‑S, supporting a bullish outlook.
Market effects
Positive signal for biotech sector as late‑stage pipeline optimism spreads.
European biotech stocks may see modest gains on the news.
Limited to investors focused on biotech and specialty pharma.
Counterpoint
The $8‑$9 bn NPV assumptions may be optimistic; execution risk remains high.
Key entities
- companyGenmab A/S
Danish biotech firm developing antibody‑drug conjugates.
- analystGuggenheim
Equity research firm that raised the price target.
